Study of GMI-1070 for the Treatment of Sickle Cell Pain Crisis

• ClinicalTrials.gov Identifier: NCT01119833
• Recruitment Status: Completed
• First Posted: May 10, 2010
• Last Update Posted: May 13, 2020
• Sponsor: GlycoMimetics Incorporated
• Information provided by (Responsible Party): GlycoMimetics Incorporated

Tracking Information

• First Submitted Date: May 5, 2010
• First Posted Date: May 10, 2010
• Last Update Posted Date: May 13, 2020
• Study Start Date: May 2010
• Actual Primary Completion Date: December 2012 (Final data collection date for primary outcome measure)

Current Primary Outcome Measures (submitted: May 6, 2010)

Reduction in time to resolution of vaso-occlusive crisis [ Time Frame: Up to 7 days or resolution ]

Including pain score, feeling ready to leave the hospital, and actual time of leaving the hospital

• Original Primary Outcome Measures: Same as current

Current Secondary Outcome Measures (submitted: May 6, 2010)

• Safety during the study [ Time Frame: Up to 28 days post last dose ]
  Including changes in physical exam, lab tests, and vital signs
• Pharmacokinetics [ Time Frame: Baseline thru 36 hrs post last dose ]
  Pharmacokinetics including half-life and concentration of GMI-1070 in the blood and urine
• Markers of inflammation and cell stickiness in the blood [ Time Frame: Up thru 28 days post last dose ]

• Original Secondary Outcome Measures: Same as current
• Current Other Pre-specified Outcome Measures: Not Provided
• Original Other Pre-specified Outcome Measures: Not Provided

Descriptive Information

• Brief Title: Study of GMI-1070 for the Treatment of Sickle Cell Pain Crisis
• Official Title: A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Pharmacokinetics of GMI-1070, A Pan-Selectin Inhibitor, In Subjects Hospitalized For Sickle Cell Vaso-Occlusive Crisis
• Brief Summary: GMI-1070 is a new drug that may reduce the stickiness of cells in the blood. The purpose of this study is to evaluate whether GMI-1070 can reduce the time it takes for pain to go away in patients with vaso-occlusive crisis (also known as a sickle cell pain crisis). The study will also collect information on the safety of GMI-1070, how much of the drug is in the blood and urine, and if there are any other effects when used in patients who are in the hospital for a sickle cell pain crisis.

Detailed Description

Patients being admitted to the hospital for pain crisis may be eligible for this study. In addition, patients should be 12-60 years old and have sickle cell types SS or S-beta-thalassemia. People who take part in the study will be evaluated and then randomly assigned to receive either GMI-1070 or a placebo by IV, in addition to all other usual treatments for their pain crisis.

During the hospital stay for pain crisis, GMI-1070 or placebo will be given twice a day, and patients will be asked about their pain severity (pain score) at the beginning of the study and every few hours during their hospital stay. Their general health, vital signs, lab tests, and pain medications will also be checked on a regular basis through the hospital stay. When a patient is feeling well enough to go home, the study drug (GMI-1070 or placebo) will be stopped, and the patient may go home. Participants will be asked to come back to clinic for a check-up a few days after leaving the hospital, and one month after leaving the hospital.

• Study Type: Interventional
• Study Phase: Phase 2
• Study Design: Allocation: Randomized; Intervention Model: Parallel Assignment; Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor); Primary Purpose: Treatment

Condition

• Sickle Cell Disease
• Vaso-occlusive Crisis
• Pain Crisis

Intervention

• Drug: GMI-1070
  Intravenous GMI-1070 given twice a day during hospital stay for sickle cell pain crisis
• Drug: Placebo
  Intravenous Placebo given twice a day during hospital stay for sickle cell pain crisis
  Other Name: saline placebo

Study Arms

• Experimental: GMI-1070
  Intervention: Drug: GMI-1070
• Placebo Comparator: Placebo
  Intervention: Drug: Placebo

Publications *

• Rebelo AL, Chevalier MT, Russo L, Pandit A. Role and therapeutic implications of protein glycosylation in neuroinflammation. Trends Mol Med. 2022 Apr;28(4):270-289. doi: 10.1016/j.molmed.2022.01.004. Epub 2022 Feb 1. Review.
• Telen MJ, Wun T, McCavit TL, De Castro LM, Krishnamurti L, Lanzkron S, Hsu LL, Smith WR, Rhee S, Magnani JL, Thackray H. Randomized phase 2 study of GMI-1070 in SCD: reduction in time to resolution of vaso-occlusive events and decreased opioid use. Blood. 2015 Apr 23;125(17):2656-64. doi: 10.1182/blood-2014-06-583351. Epub 2015 Mar 2.
• Deal watch: Pfizer deal for selectin inhibitor highlights potential of glycomimetic drugs. Nat Rev Drug Discov. 2011 Dec 1;10(12):890. doi: 10.1038/nrd3622.

Recruitment Information

• Recruitment Status: Completed
• Actual Enrollment (submitted: September 18, 2018): 81
• Original Estimated Enrollment (submitted: May 6, 2010): 76
• Actual Study Completion Date: December 2013
• Actual Primary Completion Date: December 2012 (Final data collection date for primary outcome measure)

Eligibility Criteria

Inclusion Criteria:

1. 12 to 60 years of age
2. Confirmed diagnosis of sickle cell disease (HbSS or HbS-β0thalassemia)
3. Diagnosis of VOC at the time of enrollment
4. Hospitalized or in process of admission at the time of enrollment

5. Able to receive the first dose of study drug within 24 hours of initial medical evaluation in the Emergency Department/clinic for VOC;

   o Subjects treated as an outpatient within the past 48 hours for the same VOC episode may be enrolled if dosing is also expected within 24 hours of their second (admitting) presentation.

6. Documented and observed written informed consent (and assent, where applicable)

Exclusion Criteria:

1. Infection, diagnosed or strongly suspected, as evidenced by one or more of the following:

   • Fever >39°C (102.2°F)

   • In the presence of fever ≥38.5°C (101.3°F), 1 of the following:

     • Positive findings (suspicious for infection) on diagnostic tests, such as cerebral spinal fluid [CSF] evaluation, radiographs, or bacterial culture of normally sterile sites
     • Exam findings leading to diagnosed or strongly suspected bone or joint infection
     • Determination by physician that bacterial or serious systemic viral infection is likely (eg, influenza, mononucleosis)
     • Subjects may be included with uncomplicated urinary tract infections (provided they do not have fever ≥38.5° C [101.3° F] or costo-vertebral angle [CVA] tenderness), and/or suspected minor viral syndromes (upper respiratory infection symptoms but no symptoms suggestive of bacterial infection other than uncomplicated otitis media or uncomplicated streptococcal pharyngitis)

2. Acute chest syndrome, diagnosed or strongly suspected, as evidenced by a new infiltrate on chest radiograph, and 1 or more of the following:

   • Fever >39° C (102.2° F)
   • Hypoxia (confirmed by arterial blood gases [ABG] with paO2 <70 mmHg)
   • Chest pain
   • Suspicious findings on exam (tachypnea, intercostal retractions, wheezing, and/or rales)
3. Sickle cell disease (SCD) pain atypical of VOC, including hepatic or splenic sequestration, cholecystitis, or pneumonia.
4. Acute stroke, acute priapism, severe avascular necrosis of the hip/shoulder when the presenting pain is only in the affected hip/shoulder

5. Serum creatinine:

   • >1.2 mg/dL for subjects 16 to 60 years of age
   • >1.0 mg/dL for subjects 12 to 15 years of age
6. Alanine transaminase (ALT/SGPT) >2x upper limit of normal (ULN) (based on clinic laboratory normal range)
7. Hemoglobin <5 g/dL
8. Platelets <100,000/mm3
9. Recent (within the past 30 days) major surgery, hospitalization for other than VOC, documented serious bacterial infection requiring antibiotic treatment, or significant bleeding

10. Hospitalization for uncomplicated VOC, or treated with parenteral pain medications in other medical settings such as the emergency department or day hospital for uncomplicated VOC, within past 14 days.

    o Subjects may be included if treated as an outpatient within the past 48 hours for the same VOC episode.

11. Recent (within the past 90 days) cerebrovascular accident, transient ischemic attack, or seizure
12. pRBC transfusions in the past 14 days
13. Systemic steroid therapy within 48 hours prior to enrollment or expectation that therapy may be used during the study (inhaled or topical steroids are allowed)
14. For those on chronic or long-acting opioids, a change in dose in the past 14 days OR pain requiring medical attention in the past 14 days (change in opioid medication for acute pain in the past 48 hours and directly related to this VOC admission is allowed)
15. Greater than 5 episodes of hospitalization for VOC in the past 6 months (180 days)
16. Medical or psychiatric condition that, in the opinion of the investigator, may pose a risk to the subject for participation or interfere with the conduct or results of the study
17. Currently receiving, or has received within the previous 4 weeks, any other investigational agent
18. Previous administration of GMI-1070
19. Expectation that the subject will not be able to be followed for the duration of the study
20. Pregnant or lactating female; or female of childbearing potential or male unable or unwilling to comply with birth control methods or abstinence during the course of the study
21. Active use of illicit drugs and/or alcohol dependence, as determined by the investigator

Sex/Gender

• Sexes Eligible for Study: All

• Ages: 12 Years to 60 Years (Child, Adult)
• Accepts Healthy Volunteers: No
• Contacts: Contact information is only displayed when the study is recruiting subjects
• Listed Location Countries: Canada, United States

Administrative Information

• NCT Number: NCT01119833
• Other Study ID Numbers: GMI-1070-201
• Has Data Monitoring Committee: Yes
• U.S. FDA-regulated Product: Not Provided
• IPD Sharing Statement: Not Provided
• Responsible Party: GlycoMimetics Incorporated
• Study Sponsor: GlycoMimetics Incorporated
• Collaborators: Not Provided

Investigators

• Principal Investigator: Marilyn J Telen, MD; Duke University
• Study Director: Helen Thackray, MD; GlycoMimetics, Inc.

• PRS Account: GlycoMimetics Incorporated
• Verification Date: May 2020